Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Rating of “Buy” from Brokerages

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned an average recommendation of “Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $46.4286.

Several research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. XY Capital Ltd increased its stake in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the period. Finally, UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period.

Ascentage Pharma Group International Stock Down 3.6%

Shares of Ascentage Pharma Group International stock opened at $18.68 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a one year low of $16.36 and a one year high of $48.45. The business’s 50 day simple moving average is $19.21 and its two-hundred day simple moving average is $23.11.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.